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Trends in long-term relative survival from breast cancer are examined for women diagnosed in England and Wales up to 2001, using
both period and hybrid approaches. Large improvements in long-term survival are predicted. Women with breast cancer still
experience persistent excess mortality up to at least 20 years after diagnosis.
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Compared with other common malignancies, breast cancer in women
has a relatively good prognosis in the short and medium term
(Berrino et al, 2003; Coleman et al, 2004). Where long-term survival
has been examined, it has mostly been shown that women with breast
cancer continue to experience excess mortality into the second and
third decades after their diagnosis (Duncan and Kerr, 1976;
Langlands et al, 1979; Brinkley and Haybittle, 1984; Adami et al,
1986; Zahl and Tretli, 1997; Joensuu et al, 1999). This excess mortality
may be due to the existence of ‘micro-metastases’ – disseminated
cancer cells present even in women with apparently localised disease
at diagnosis (Slade et al, 2005). Because previous survival studies
have been based on cohort or complete approaches, trends in long-
term survival have involved women diagnosed from the 1940s up to
the 1970s, at least 10 years before the important advances in
diagnosis and management that occurred during the 1980s.
We have used statistical methods designed to reflect the recent gains
in short-term survival, to provide the most ‘up-to-date’ predictions of
long-term survival possible, namely for women diagnosed in England
and Wales during the period 1971–2001 and followed up to 2003.
MATERIALS AND METHODS
Data were obtained from the Office for National Statistics on all
women diagnosed in England and Wales with invasive breast
cancer in 1971–2001 and followed up until 31 December 2003. To
these, we applied the inclusion and exclusion criteria recently
reported (Coleman et al, 2004), before estimating relative survival
up to 20 years after diagnosis. Relative survival estimates the
disease-specific survival by subtracting the background general
population mortality from the overall mortality observed among
the cancer patients. It is the most defensible method of examining
long-term disease survival, because it does not rely upon accurate
reporting of cause of death (Ederer et al, 1961). We used both
period and hybrid approaches to estimate relative survival and
they are contrasted with the classical cohort approach in Figure 1.
The period approach (Brenner and Gefeller, 1997) derives the
most up-to-date estimates of survival by incorporating the
probabilities of death derived from the most recent year or period
for which follow-up data are available, while excluding survival
probabilities derived from earlier periods (left censoring). The
calculation of period survival is analogous to that of life
expectancy at birth from a period life table. It was used to produce
sets of estimates of long-term survival for women with breast
cancer who were alive at some point either during the period
1991–1993 or during 1996–1998. These period survival estimates
are best interpreted as the predicted probability of survival for a
patient diagnosed within those periods.
Hybrid analysis is a modification of the period approach that
combines both cohort and period techniques (Brenner and Rachet,
2004). It is preferable in scenarios where information on the patients’
vital status becomes available more rapidly than the reporting of
incident cases, because it enables unbiased estimates of survival; it
was applied for the period 1999–2003. Cohort survival estimates from
the first and second years of follow-up for women diagnosed during
1999–2001 were combined with period estimates of relative survival
for the third to twentieth years of follow-up observed among women
alive at any point during the interval 2001–2003 (Figure 1).
Relative survival rates were all estimated with a maximum likelihood
approach for individual tumour data (Este `ve et al, 1990) using the
algorithm strel (Cancer Research UK Cancer Survival Group, 2006)
implemented in STATAt (StataCorp, 2006). Background mortality was
taken from period- and deprivation-specific national life tables in every
analysis (Cancer Research UK Cancer Survival Group, 2004). Survival
estimates were derived for all women aged 15–99 years at diagnosis,
and separately for the three broad age groups 15–49, 50–69 and 70–99
years. Changes in survival over a 10-year period were derived from a
variance-weighted linear regression of survival estimates for the periods
1991–1993, 1996–1998 and 1999–2003. Overall survival estimates for
all women aged 15–99 years at diagnosis were age-standardised using
the population structure of women diagnosed with breast cancer in
England and Wales during the period 1986–1990, to enable
comparison with published data (Coleman et al, 1999, 2004).
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Overall predicted long-term survival has improved markedly since
1991–1993, with a 17–20% improvement in predicted 10- and 20-
year relative survival over the 10-year interval from 1991–1993 to
1999–2003 (Table 1). The predicted improvement in long-term
survival was better for women aged 50 and over at diagnosis (18–
24%), than for those aged 15–49 years (13–14%).
Overall 10-year relative survival, for all women diagnosed with
invasive breast cancer in England and Wales between 1999 and
2003 in the age range 15–99 years, is predicted to exceed 72%.
More than 64% of recently diagnosed women are predicted to
survive to the 20th anniversary of their diagnosis.
In 1991–1993, women diagnosed at ages 15–49 years had higher
predicted 10-, 15- and 20-year survival than older women, but a decade
later, their predicted survival was lower than for women diagnosed
aged 50–69 years (Figure 2). By contrast, 1-year survival rates and
trends were very similar in these age groups (data not shown). Older
women (70–99 years) experienced the lowest survival, particularly 10
years after diagnosis (63%). However, although the difference between
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Figure 2 Predicted trends up to 2003 in 10-year relative survival (%) from breast cancer, by age at diagnosis, with 95% confidence intervals: women,
England and Wales.
Table 1 Trends in long-term relative survival (%) predicted for women diagnosed with invasive breast cancer during 1991–1993, 1996–1998 and
1999–2003, by age at diagnosis and time since diagnosis: England and Wales
Calendar period of follow-up used in the analyses
1991–1993 (period approach) 1996–1998 (period approach) 1999–2003 (hybrid approach)
Age at
diagnosis Women
a Deaths
Relative
survival
(95% CI) Women
a Deaths
Relative
survival
(95% CI) Women
a Deaths
Relative
survival
(95% CI)
10-year change
b
in relative survival
(95% CI)
Time since diagnosis
All ages (15–99), age-standardised
10 years 256954 48423 54.3 (53.8–54.9) 314026 49216 63.7 (63.2–64.3) 329498 62038 71.5 (71.0–72.0) 17.1 (16.4–17.9)
15 years 47.8 (46.9–48.7) 56.4 (55.5–57.3) 67.3 (66.4–68.1) 19.5 (18.2–20.8)
20 years 44.4 (43.1–45.7) 52.0 (50.8–53.3) 64.3 (62.9–65.7) 19.7 (17.9–21.6)
15–49 years
10 years 67553 7451 60.2 (59.4–61.0) 82750 7665 66.6 (65.9–67.3) 84871 8842 73.0 (72.4–73.7) 12.8 (11.8–13.9)
15 years 54.0 (53.1–54.9) 60.2 (59.3–61.0) 67.6 (66.8–68.3) 13.7 (12.5–14.8)
20 years 49.8 (48.8–50.8) 55.8 (54.8–56.7) 63.4 (62.5–64.2) 13.7 (12.3–15.0)
50–69 years
10 years 125214 19236 59.7 (59.0–60.4) 154006 18524 70.8 (70.2–71.4) 165459 21445 79.1 (78.6–79.6) 19.1 (18.3–20.0)
15 years 51.9 (51.1–52.7) 62.7 (61.9–63.5) 75.2 (74.6–75.9) 23.5 (22.4–24.5)
20 years 48.0 (47.0–49.0) 57.6 (56.6–58.6) 71.7 (70.7–72.6) 23.8 (22.3–25.2)
70–99 years
10 years 64187 21736 45.0 (43.8–46.1) 77270 23027 54.9 (53.6–56.1) 79168 31751 62.6 (61.4–63.7) 17.6 (16.0–19.2)
15 years 39.1 (37.4–40.8) 46.7 (44.9–48.5) 59.0 (57.1–60.8) 19.7 (17.2–22.3)
20 years 37.4 (33.9–41.0) 43.2 (40.1–46.3) 58.7 (55.2–62.0) 21.4 (16.5–26.3)
aNumber of women alive at some point during the period of follow-up used in the analyses.
b10-year change in relative survival (absolute fitted increase, %) derived from a
variance-weighted linear regression of relative survival estimates for the periods 1991–1993, 1996–1998 and 1999–2003.
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women diagnosed in 1991–1993 (about 10%), the difference was less
marked among older women diagnosed since 1999. This reflects the
larger recent increase in long-term survival among women aged 50 and
over than among those aged 15–49 years.
DISCUSSION
This study predicts substantial increases in long-term survival from
invasive breast cancer among women diagnosed over the period 1991–
2003, particularly for those aged 50 years or more. It also shows
persisting excess mortality up to at least 20 years after diagnosis.
We have previously documented large and continuing improve-
ments in survival in England and Wales over this period using
conventional approaches (Coleman et al, 1999, 2004). This study
extends those reports by providing predictions of long-term
survival for women diagnosed very recently, as well as demon-
strating how this predicted survival has changed over time.
The rising trend in long-term survival in breast cancer in England
and Wales probably reflects the combined impact of several
important changes in its diagnosis and management over the last
two decades. These include the widespread adoption of adjuvant
chemotherapy, as recommended by the 1985 world overview (Baum
and Houghton, 1999), the increasing use of hormonal-based
treatments in England and Wales, particularly for post-menopausal
women, the use of radiotherapy after breast-conserving surgery (Early
Breast Cancer Trialists’ Collaborative Group, 2005) and the establish-
ment of the National Health Service Breast Screening Programme for
women aged 50–64 years in 1988 (Quinn et al, 1995).
In this period-based approach, the survival improvements
described reflect the impact of very recent changes in breast
cancer management upon short-term survival, combined with the
impact of less recent changes upon longer-term survival. Conse-
quently, although the survival rates reported here are more ‘up-to-
date’ than conventional estimates, even period estimates cannot yet
reflect the full potential impact of recent advances in the diagnosis
and treatment of breast cancer on long-term survival, because
women contributing to the survival estimates for the 15th to 20th
years of follow-up were diagnosed before those advances were
made (Figure 1). A further 5–10 years of incidence and follow-up
data will enable the impact of these changes in diagnosis and
management upon very long-term survival to be formally assessed.
Comparing the 10-year survival rates with those estimated for 15–20
years after diagnosis shows that relative survival for breast cancer
continues to decrease throughout the two decades following diagnosis.
This is consistent both with early work, and with a more recent analysis
of women diagnosed with breast cancer in Finland up to 1999 (Brenner
and Hakulinen, 2004). Our data further suggest that this tendency
applies to women diagnosed as recently as 1981 and that it has not
diminished over time, although it is not yet possible to assess the
impact of the changes implemented during the late 1980s upon survival
beyond 15 years after diagnosis.
Our study highlights the much better prognosis for women
diagnosed in the first few years of the twenty-first century than for
women diagnosed during the early 1990s. However, the continued
existence of late mortality from breast cancer suggests that the
treatments given for breast cancer, at least up to the mid-to-late
1980s, have not yet eliminated the continuing risk of death due to
the disease more than 10 years after initial diagnosis.
ACKNOWLEDGEMENTS
We gratefully acknowledge the work of our many colleagues in the
cancer registries of England and Wales, who have over several
decades collected individual cancer patient data for collation by
the National Cancer Registry at the Office for National Statistics:
these analyses would not have been possible without data on
cancer patients diagnosed as early as 1971. We also thank the staff
at the National Health Service Central Register at Southport, who
followed up all the patients for their vital status.
REFERENCES
Adami H-O, Malker B, Rutqvist LE, Persson I, Ries LAG (1986) Temporal
trends in breast cancer survival in Sweden: significant improvement in
20 years. J Natl Cancer Inst 76: 653–659
Baum M, Houghton J (1999) Contribution of randomised controlled trials
to understanding and management of early breast cancer. Br Med J 319:
568–571
Berrino F, Capocaccia R, Coleman MP, Este `ve J, Gatta G, Hakulinen T,
Micheli M, Sant M, Verdecchia A (eds.) (2003) Survival of cancer patients
in Europe: the EUROCARE-3 study. Ann Oncol 14(Suppl 5): v1–v155
Brenner H, Gefeller O (1997) Deriving more up-to-date estimates of long-
term patient survival. J Clin Epidemiol 50: 211–216
Brenner H, Hakulinen T (2004) Are patients diagnosed with breast cancer
before age 50 years ever cured? J Clin Oncol 22: 432–438
Brenner H, Rachet B (2004) Hybrid analysis for up-to-date long-term
survival rates in cancer registries with delayed recording of incident
cases. Eur J Cancer 40: 2494–2501
Brinkley D, Haybittle JL (1984) Long-term survival of women with breast
cancer. Lancet i: 1118
Cancer Research UK Cancer Survival Group (2004) Life tables for England
and Wales by sex, calendar period, region and deprivation. London
School of Hygiene and Tropical Medicine, www.lshtm.ac.uk/ncdeu/
cancersurvival/tools/strelandlifetables.htm
Cancer Research UK Cancer Survival Group (2006) strel Computer
Program Version 5.8 for Cancer Survival Analysis. London School of
Hygiene and Tropical Medicine www.lshtm.ac.uk/ncdeu/cancersurvival/
tools.htm
Coleman MP, Babb P, Damiecki P, Grosclaude PC, Honjo S, Jones J, Knerer
G, Pitard A, Quinn MJ, Sloggett A, De Stavola BL (1999) Cancer Survival
Trends in England and Wales 1971-1995: Deprivation and NHS Region.
Series SMPS No. 61. London: Office for National Statistics
Coleman MP, Rachet B, Woods LM, Mitry E, Riga M, Cooper N, Quinn MJ,
Brenner H, Este `ve J (2004) Trends and socio-economic inequalities in cancer
survival in England and Wales up to 2001. Br J Cancer 90: 1367–1373
Duncan W, Kerr GR (1976) The curability of breast cancer. Br Med J 2:
781–783
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of
radiotherapy and of differences in the extent of surgery for early breast
cancer on local recurrence and 15-year survival: an overview of the
randomised trials. Lancet 366: 2087–2106
Ederer F, Axtell LM, Cutler SJ (1961) The relative survival: a statistical
methodology. Natl Cancer Inst Monogr 6: 101–121
Este `ve J, Benhamou E, Croasdale M, Raymond L (1990) Relative survival
and the estimation of net survival: elements for further discussion. Stat
Med 9: 529–538
Joensuu H, Pylkka ¨nen L, Toikkanen S (1999) Late mortality from pT1N0M0
breast carcinoma. Cancer 85: 2183–2189
Langlands AO, Pocock SJ, Kerr GR, Gore SM (1979) Long-term survival of
patients with breast cancer: a study of the curability of the disease. BMJ 2:
1247–1251
Quinn MJ, Allen E, UK Association of Cancer Registries (1995) Changes in
incidence of and mortality from breast cancer in England and Wales
since introduction of screening. BMJ 311: 1391–1393
Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S,
Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC (2005)
Persistence of bone marrow micrometastases in patients receiving adjuvant
therapy for breast cancer: results at 4 years. Int J Cancer 114: 94–100
StataCorp (2006) STATA statistical software. College Station, TX: Stata
Corporation
Zahl P-H, Tretli S (1997) Long-term survival of breast cancer in Norway by
age and clinical stage. Stat Med 16: 1435–1449
Predicted trends in long-term breast cancer survival
LM Woods et al
1138
British Journal of Cancer (2007) 96(7), 1135–1138 & 2007 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y